July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.
Labcorp Plasma Detect is a blood-based test using whole genome sequencing to detect circulating tumor DNA, indicating the presence of molecular residual disease. Results are available about 14 days after Labcorp receives the initial sample and seven days for subsequent monitoring time points for each patient. The test, for clinical use, will be initially offered through an early experience program, with the intent to expand availability.
The PGDx Elio Plasma Focus Dx assay provides actionable findings within a four- to five-day turnaround time, from isolated nucleic acid to variant report, and requires only onsite verification, as opposed to a full validation, the company says. The kitted model is compatible with the FDA-cleared PGDx Elio Tissue Complete.
Labcorp, 336-229-1127